Pharma4ever Engineering ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 11.0% 9.6% 5.0% 6.0%  
Credit score (0-100)  0 21 25 43 39  
Credit rating  N/A BB BB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  0.0 1,056 3,835 14,793 14,220  
EBITDA  0.0 124 906 3,891 1,517  
EBIT  0.0 124 906 3,891 1,517  
Pre-tax profit (PTP)  0.0 102.7 861.1 3,875.8 1,336.2  
Net earnings  0.0 77.9 670.6 3,019.9 1,037.8  
Pre-tax profit without non-rec. items  0.0 103 861 3,876 1,336  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 118 788 3,158 1,078  
Interest-bearing liabilities  0.0 0.0 743 0.0 0.0  
Balance sheet total (assets)  0.0 287 3,237 7,999 7,473  

Net Debt  0.0 -145 18.2 -2,639 -973  
 
See the entire balance sheet

Volume 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 1,056 3,835 14,793 14,220  
Gross profit growth  0.0% 0.0% 263.1% 285.7% -3.9%  
Employees  0 1 3 11 13  
Employee growth %  0.0% 0.0% 200.0% 266.7% 18.2%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 287 3,237 7,999 7,473  
Balance sheet change%  0.0% 0.0% 1,029.6% 147.1% -6.6%  
Added value  0.0 123.9 906.3 3,891.2 1,516.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 1.0 2.0 3.0 4.0  

Profitability 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 11.7% 23.6% 26.3% 10.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 43.2% 51.5% 69.3% 19.7%  
ROI %  0.0% 105.1% 109.9% 166.1% 71.8%  
ROE %  0.0% 66.1% 148.0% 153.0% 49.0%  

Solidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 41.1% 24.4% 39.5% 14.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -117.2% 2.0% -67.8% -64.1%  
Gearing %  0.0% 0.0% 94.2% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 12.2% 4.9% 0.0%  

Liquidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.0 1.7 1.3 1.7 1.2  
Current Ratio  0.0 1.7 1.3 1.7 1.2  
Cash and cash equivalent  0.0 145.3 724.5 2,638.5 972.7  

Capital use efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 117.9 788.4 3,158.4 1,077.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 124 302 354 117  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 124 302 354 117  
EBIT / employee  0 124 302 354 117  
Net earnings / employee  0 78 224 275 80